rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open label, plus expansion clinical trial evaluating the safety and
tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax
is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting
neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG
and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
Phase:
Phase 1
Details
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators:
Children's Hospital of Orange County Dana-Farber Cancer Institute